"doi";"field";"value_source_1";"value_source_2"
"10.1101/2022.03.29.22273148";"registration_statement";"FALSE";"TRUE"
"10.1101/2022.04.03.22273268";"sciscore";"1";"2"
"10.1101/2022.04.03.22273268";"ethics_value1";"notrequired.";"Ethics approval: The Institutional Review Board of the Clinical Research and Genome Research Committee at Yamanashi Central Hospital approved this study and the use of an opt-out consent method (Approval No. C2019-30)."
"10.1101/2022.04.03.22273268";"Inclusion and Exclusion Criteria";"notrequired.";"notdetected."
"10.1101/2022.04.03.22273268";"Attrition";"notrequired.";"notdetected."
"10.1101/2022.04.03.22273268";"Sex as a biological variable";"notrequired.";"notdetected."
"10.1101/2022.04.03.22273268";"Subject Demographics";"notrequired.";"notdetected."
"10.1101/2022.04.03.22273268";"ethics_statement_detected";"FALSE";"TRUE"
"10.1101/2022.04.03.22273268";"ethics_titles";"NA,NA,NA";"IRB,Consent,NA"
"10.1101/2022.04.03.22273268";"has_consent";"FALSE";"TRUE"
"10.1101/2022.04.03.22273268";"has_IRB_or_consent";"FALSE";"TRUE"
"10.1101/2022.04.04.22273344";"Power Analysis";"notdetected.";"Sample size and recruitment methods: The sample size was estimated using the double population proportion formula by the statcalc program of Epi info software, considering unmatched case-control study assumptions."
"10.1101/2022.04.04.22273344";"power_analysis_detected";"FALSE";"TRUE"
"10.1101/2022.04.05.22272397";"sciscore";"1";"4"
"10.1101/2022.04.05.22272397";"funding_statement";"FALSE";"TRUE"
"10.1101/2022.04.05.22273473";"limitations";"17";"0"
"10.1101/2022.04.05.22273473";"Sex as a biological variable";"Data extraction and management Following specific information will be extracted: (a) study characteristics include title, author names, journal of publication, year, follow-up durations, etc. (b) participant/population characteristics including sample sizes, proportions of males, age, etc.";"notdetected."
"10.1101/2022.04.05.22273473";"registration_statement";"FALSE";"TRUE"
"10.1101/2022.04.05.22273473";"limitations_detected";"TRUE";"FALSE"
"10.1101/2022.04.05.22273473";"sex_variable_detected";"TRUE";"FALSE"
"10.1101/2022.04.06.22273512";"coi_statement";"FALSE";"TRUE"
"10.1101/2022.04.06.22273514";"Randomization";"33] (Figure 1) [ Figure 1] STIMULATE-ICP is funded by the National Institute for Health Research (NIHR: COV-LT2- 0043)[34] and combines clinical epidemiological studies, a complex randomised trial exploring the benefit of an ICP for Long COVID (IRAS: 1004698), and mixed methods studies exploring inequalities of care and transferability of the ICP to other LTCs (IRAS: 303958).";"Study design and procedures: This STIMULATE-ICP-DELPHI sub-study of the STIMULATE-ICP project (Symptoms, Trajectory, Inequalities and Management: Understanding Long COVID to Address and Transform Existing Integrated Care Pathways).(33) (Figure 1) STIMULATE-ICP is funded by the National Institute for Health Research (NIHR: COV-LT2-0043)(34) and combines clinical epidemiological studies, a complex randomised trial exploring the benefit of an ICP for Long COVID (IRAS: 1004698), and mixed methods studies exploring inequalities of care and transferability of the ICP to other LTCs (IRAS: 303958)."
"10.1101/2022.04.06.22273514";"funding_statement";"FALSE";"TRUE"
"10.1101/2022.04.06.22273526";"coi_statement";"FALSE";"TRUE"
"10.1101/2022.04.06.22273526";"funding_statement";"FALSE";"TRUE"
"10.1101/2022.04.06.22273535";"trial_n_detected";"TRUE";"FALSE"
"10.1101/2022.04.06.22273535";"funding_statement";"FALSE";"TRUE"
"10.1101/2022.04.06.487394";"jet_pages";"1";"0"
"10.1101/2022.04.06.487394";"has_jet_pages";"TRUE";"FALSE"
"10.1101/2022.04.07.22273430";"sciscore";"2";"3"
"10.1101/2022.04.07.22273430";"registration_statement";"FALSE";"TRUE"
"10.1101/2022.04.07.22273561";"sciscore";"1";"6"
"10.1101/2022.04.07.22273561";"ethics_value1";"notrequired.";"We adopted the study design from a previous study evaluating the effect of COVID-19 measures on health care use in the UK.(Mansfield et al. 2021) The Human Research Ethics Committee of the University of Cape Town and the Cantonal Ethics Committee of the Canton of Bern granted permission to analyse the data."
"10.1101/2022.04.07.22273561";"Inclusion and Exclusion Criteria";"notrequired.";"Individuals with missing information on sex or age were excluded."
"10.1101/2022.04.07.22273561";"Attrition";"notrequired.";"notdetected."
"10.1101/2022.04.07.22273561";"Subject Demographics";"Methods We did an interrupted time series analysis using insurance claims from January 1, 2017, to June 1, 2020 of beneficiaries 18 years or older from a large private sector medical aid scheme.";"Study population: We followed beneficiaries of one of South Africa’s largest open medical schemes that insured over 700,000 individuals as of 2019.(Council for Medical Schemes 2020) It has a young membership base with an average age of about 33.(Council for Medical Schemes 2020) We included beneficiaries aged 18 years or older who had an active health care plan between January 1, 2017, and June 28, 2020."
"10.1101/2022.04.07.22273561";"ethics_statement_detected";"FALSE";"TRUE"
"10.1101/2022.04.07.22273561";"inclusion_criteria_detected";"FALSE";"TRUE"
"10.1101/2022.04.07.22273561";"ethics_titles";"NA,NA,NA";"IRB,NA,NA"
"10.1101/2022.04.07.22273561";"has_IRB_only";"FALSE";"TRUE"
"10.1101/2022.04.07.22273593";"Inclusion and Exclusion Criteria";"* Booster shot (any booster shot after completing initial vaccine schedule) At the start of 2022, all MA residents ages 5 and over were eligible to be vaccinated, and all residents ages 12 and over were eligible for the booster.";"We extracted data on two key constructs reported in the MA DPH vaccine database: At the start of 2022, all MA residents ages 5 and over were eligible to be vaccinated, and all residents ages 12 and over were eligible for the booster."
"10.1101/2022.04.07.22273593";"Sex as a biological variable";"The ZIP-code-by-sex data were nearly complete for self-identified ""males"" and ""females"".";"Data for the category “neither male nor female” were frequently suppressed due to small numbers (70% of ZIP codes were missing data on this group for vaccines, and 92% were missing data on boosters)."
"10.1101/2022.04.07.22273593";"Subject Demographics";"Using the Census ACS estimates we derived zip code level ""percent college graduates over the age of 25 years"", ""percent Black, Latino, or Indigenous"", ""percent essential workers"", and ""median household income"".";"We additionally constructed a series of variables to capture differences in age composition across ZIP codes: % of ZIP-code residents aged 0-4 years, % 5-19 years, % 20-39 years, % 40-64 years, % 65+ years."
"10.1101/2022.04.07.22273593";"coi_statement";"FALSE";"TRUE"
"10.1101/2022.04.07.487460";"trial_n_detected";"TRUE";"FALSE"
"10.1101/2022.04.08.22273602";"trial_n_detected";"TRUE";"FALSE"
"10.1101/2022.04.08.22273605";"jet_pages";"1";"0"
"10.1101/2022.04.08.22273605";"sciscore";"3";"4"
"10.1101/2022.04.08.22273605";"has_jet_pages";"TRUE";"FALSE"
"10.1101/2022.04.08.22273608";"ethics_value2";"The research protocol was approved by the Ethics Committee for Research with Human Beings of Universidade Evangelica (UNIEVANGELICA) on September 24, 2020, under protocol number 4,235,203.";"The research protocol was approved by the Ethics Committee for Research with Human Beings of Universidade Evangélica de Goiás (UNIEVANGÉLICA) on September 24, 2020, under protocol number 4,235,203."
"10.1101/2022.04.08.22273608";"Inclusion and Exclusion Criteria";"Inclusion criteria The following are the inclusion criteria: Age 16-75 years Patients who have been affected by COVID-19 and with impaired lung function clinical trial was registered at ClinicalTrials.gov (ID: de Goias COVID-19 Clinically stabilized patients Patients who agreed to participate in the pulmonary rehabilitation program for at least 12 weeks and signed a free and informed consent form Exclusion criteria The following are the exclusion criteria: Hospitalized patients Patients affected with chronic neurological diseases that make it impossible to understand and perform physical activities Patients suffering from hypertension and cardiovascular conditions without medical treatment Patients affected with acute phase of rheumatologic disorders Patients who have recent musculoskeletal disorders and who are not fully recovered from their injuries Patients affected with chronic mental and/or psychological disturbances Presence of terminal neoplastic disease Red flags for serious conditions (night pain, severe muscle spasm, loss of involuntary weight, and symptom mismatch) Patients classified as severe cases according to the following criteria will also be excluded.";"Participants: recruitment and eligibility criteria: To be involved in this clinical study, according to the inclusion criteria, women and men aged between 16 and 75 years affected by COVID-19 will be invited."
"10.1101/2022.04.08.22273608";"Sex as a biological variable";"To be involved in this clinical study, according to the inclusion criteria, women and men aged between 16 and 75 years affected by COVID-19.";"Participants: recruitment and eligibility criteria: To be involved in this clinical study, according to the inclusion criteria, women and men aged between 16 and 75 years affected by COVID-19 will be invited."
"10.1101/2022.04.08.22273608";"Subject Demographics";"Inclusion criteria The following are the inclusion criteria: Age 16-75 years Patients who have been affected by COVID-19 and with impaired lung function clinical trial was registered at ClinicalTrials.gov (ID: de Goias COVID-19 Clinically stabilized patients Patients who agreed to participate in the pulmonary rehabilitation program for at least 12 weeks and signed a free and informed consent form Exclusion criteria The following are the exclusion criteria: Hospitalized patients Patients affected with chronic neurological diseases that make it impossible to understand and perform physical activities Patients suffering from hypertension and cardiovascular conditions without medical treatment Patients affected with acute phase of rheumatologic disorders Patients who have recent musculoskeletal disorders and who are not fully recovered from their injuries Patients affected with chronic mental and/or psychological disturbances Presence of terminal neoplastic disease Red flags for serious conditions (night pain, severe muscle spasm, loss of involuntary weight, and symptom mismatch) Patients classified as severe cases according to the following criteria will also be excluded.";"Inclusion criteria: The following are the inclusion criteria: Age 16–75 years Patients who have been affected by COVID-19 and with impaired lung function Clinically stabilized patients Patients who agreed to participate in the pulmonary rehabilitation program for at least 12 weeks and signed a free and informed consent form Exclusion criteria: The following are the exclusion criteria: Hospitalized patients Patients affected with chronic neurological diseases that make it impossible to understand and perform physical activities Patients suffering from hypertension and cardiovascular conditions without medical treatment Patients affected with acute phase of rheumatologic disorders Patients who have recent musculoskeletal disorders and who are not fully recovered from their injuries Patients affected with chronic mental and/or psychological disturbances Presence of terminal neoplastic disease Red flags for serious conditions (night pain, severe muscle spasm, loss of involuntary weight, and symptom mismatch) Patients classified as severe cases according to the following criteria will also be excluded."
"10.1101/2022.04.08.22273608";"Blinding";"Methods This study will be a cohort, parallel, two-arm multicentric study, to be carried out in three clinical centers, with blind evaluation, with 06 weeks of training and follow-up.";"Study design: This study will be a cohort, parallel, two-arm multicentric study, to be carried out in three clinical centers, with blind transversal and longitudinal evaluation, with 06 weeks of training and follow-up."
"10.1101/2022.04.08.22273608";"is_modeling_paper";"TRUE";"FALSE"
"10.1101/2022.04.11.22272784";"limitations";"10";"0"
"10.1101/2022.04.11.22272784";"sciscore";"4";"5"
"10.1101/2022.04.11.22272784";"Randomization";"Root-to-tip analysis To examine the rate at which the patient's virus accumulated mutations, and compare that rate with SARS-CoV-2 globally, we randomly subsampled approximately 5,000 SARS-CoV-2 sequences from NCBI GenBank.";"Root-to-tip analysis: To examine the rate at which the patient’s virus accumulated mutations, and compare that rate with SARS-CoV-2 globally, we randomly subsampled approximately 5,000 SARS-CoV-2 sequences 33 from the GISAID global dataset using scripts made available in the Nextstrain command line interface 34."
"10.1101/2022.04.11.22272784";"limitations_detected";"TRUE";"FALSE"
"10.1101/2022.04.11.22273709";"sciscore";"2";"5"
"10.1101/2022.04.11.22273709";"Inclusion and Exclusion Criteria";"notrequired.";"Included studies met the following criteria: (i) patients were diagnosed with COVID-19 based on the WHO criteria; (ii) patients were received anti-depressants; and (iii) severity predictors (hospitalization due to COVID-19 and/or ARDS and/or need to NIV or mechanical ventilation and/or ICU admission and/or death)."
"10.1101/2022.04.11.22273709";"Blinding";"notdetected.";"Quality assessment: Two blinded reviewers assessed the quality of the studies using three different assessment tools (checklists): two for observational studies (case controls and cohorts) and one for experimental studies (14)."
"10.1101/2022.04.11.22273709";"funding_statement";"FALSE";"TRUE"
"10.1101/2022.04.11.22273709";"blinding_detected";"FALSE";"TRUE"
"10.1101/2022.04.11.22273709";"inclusion_criteria_detected";"FALSE";"TRUE"
"10.1101/2022.04.12.22273761";"Attrition";"Five probes were designed to be selective for each of the mutations (Table 1, 2), as well as a universal probe for the ""Universal"" probe complementary to a nearby, highly conserved (bp 28891-28905, mutation rates <0.87% according to covidcg.";"Five probes were designed to be selective for each of the mutations (Table 1, 2), as well as a universal probe for the “Universal” probe complementary to a nearby, highly conserved (bp 28891-28905, mutation rates <0.87% according to covidcg.org) region of the amplicon to detect total SARS-CoV-2"
"10.1101/2022.04.12.22273761";"coi_statement";"FALSE";"TRUE"
"10.1101/2022.04.12.488010";"Sex as a biological variable";"notdetected.";"In-vivo experiments: Male Golden Syrian hamsters age 6-8 week were treated with siRNA cocktails at days −7, −3 and −1 pre-infection."
"10.1101/2022.04.12.488010";"coi_statement";"FALSE";"TRUE"
"10.1101/2022.04.12.488010";"sex_variable_detected";"FALSE";"TRUE"
"10.1101/2022.04.13.22273817";"coi_statement";"FALSE";"TRUE"
"10.1101/2022.04.13.22273817";"funding_statement";"FALSE";"TRUE"
"10.1101/2022.04.13.22273832";"trial_n_detected";"TRUE";"FALSE"
"10.1101/2022.04.13.22273832";"Inclusion and Exclusion Criteria";"Data that did not relate to the key findings outlined above were excluded from this portion of the analysis.";"The four key findings identified from the NICE report were: Data that did not relate to the key findings outlined above were excluded from this portion of the analysis."
"10.1101/2022.04.13.488249";"coi_statement";"FALSE";"TRUE"
"10.1101/2022.04.14.22273858";"sciscore";"1";"6"
"10.1101/2022.04.14.22273858";"ethics_value1";"notrequired.";"Starting from a precompiled list of 18 references based on our primary research on the effects of non-pharmaceutical interventions, we created and repeatedly extended a collection of synonyms for each of the above components, thereby achieving a broad search while keeping the number of selected studies manageable."
"10.1101/2022.04.14.22273858";"Inclusion and Exclusion Criteria";"notrequired.";"In contrast, we excluded analyses assessing the effects of non-pharmaceutical interventions solely on other outcomes not directly related to infectious diseases (e. g. psychological well-being or economic activities)."
"10.1101/2022.04.14.22273858";"Attrition";"(i) Description of change over time The large majority of analyses following a descriptive approach examined the change of the outcome over time to assess the intervention effect (n=136; 48 %).";"notrequired."
"10.1101/2022.04.14.22273858";"Blinding";"notdetected.";"During the first round, two authors (AL and NB) extracted data from an initial set of 20 publications, blinded to each other’s coding."
"10.1101/2022.04.14.22273858";"blinding_detected";"FALSE";"TRUE"
"10.1101/2022.04.14.22273858";"ethics_statement_detected";"FALSE";"TRUE"
"10.1101/2022.04.14.22273858";"inclusion_criteria_detected";"FALSE";"TRUE"
"10.1101/2022.04.14.22273858";"attrition_detected";"TRUE";"FALSE"
"10.1101/2022.04.14.22273858";"ethics_titles";"NA,NA,NA";"Field Sample Permit,NA,NA"
"10.1101/2022.04.14.22273860";"registration_statement";"FALSE";"TRUE"
"10.1101/2022.04.14.22273903";"trial_n_detected";"TRUE";"FALSE"
"10.1101/2022.04.14.22273903";"is_modeling_paper";"FALSE";"TRUE"
"10.1101/2022.04.14.22273903";"funding_statement";"TRUE";"FALSE"
"10.1101/2022.04.15.22273915";"coi_statement";"FALSE";"TRUE"
"10.1101/2022.04.16.22273937";"Inclusion and Exclusion Criteria";"Eligibility criteria 1.";"Eligibility criteria: Data extraction and selection process: Every step of the data extraction process from the original source was guided by PRISMA 2020, which was used to guide the process."
"10.1101/2022.04.17.22273949";"sciscore";"3";"4"
"10.1101/2022.04.17.22273949";"Randomization";"Downsampling simulation In order to estimate the SARS-CoV-2 N gene and PMMoV RNA concentration we would have obtained if we had run a smaller number of wells (X = 1 - 9), we randomly selected X wells from the 10 wells to calculate the resultant concentration: number of negative droplets Concentration (cp/L) = -ln = / 0.00085L total accepted droplets where 0.00085 mL is the volume of a single droplet14.";"Downsampling simulation: In order to estimate the SARS-CoV-2 N gene and PMMoV RNA concentration we would have obtained if we had run a smaller number of wells (X = 1 - 9), we randomly selected X wells from the 10 wells to calculate the resultant concentration:where 0.00085 μL is the volume of a single droplet14."
"10.1101/2022.04.19.488843";"trial_n_detected";"TRUE";"FALSE"
"10.1101/2022.04.20.485440";"sciscore";"2";"3"
"10.1101/2022.04.20.485440";"ethics_value1";"Methods Ethics The animal experiments were evaluated and approved by the ethics committee of the State Office of Agriculture, Food safety, and Fishery in Mecklenburg - Western Pomerania (LALLF M-V: LVL MV/TSD/7221.3-1-055/20) and the State Office for Occupational Safety, Consumer Protection and Health in Brandenburg (LAVG: 2347-5-2021).";"Ethics: The animal experiments were evaluated and approved by the ethics committee of the State Office of Agriculture, Food safety, and Fishery in Mecklenburg–Western Pomerania (LALLF M-V: LVL MV/TSD/7221.3-1-055/20) and the State Office for Occupational Safety, Consumer Protection and Health in Brandenburg (LAVG: 2347-5-2021)."
"10.1101/2022.04.20.485440";"coi_statement";"FALSE";"TRUE"
"10.1101/2022.04.21.22274139";"coi_statement";"FALSE";"TRUE"
"10.1101/2022.04.21.22274150";"sciscore";"3";"6"
"10.1101/2022.04.25.22274283";"sciscore";"7";"4"
"10.1101/2022.04.25.22274283";"Subject Demographics";"The study will recruit and enroll up to 375 community dwelling older adults (age 60 or older) to reach the target number of randomized subjects of n=150 in each group.";"Participants: The study will recruit and enroll up to 375 community dwelling older adults (age 60 or older) to reach the target number of randomized subjects of n=150 in each group."
"10.1101/2022.04.25.22274283";"Randomization";"This is a randomized trial registered at clinicaltrials.gov (NCT03343483).";"Study design, setting, ethical considerations: This is a randomized trial registered at clinicaltrials.gov (NCT03343483)."
"10.1101/2022.04.25.22274283";"Power Analysis";"Sample size calculation.";"Sample size calculation: A power analysis was conducted to test treatment effects by the intent-to-treat (ITT) analysis for the primary outcomes."
"10.1101/2022.04.25.22274283";"is_modeling_paper";"TRUE";"FALSE"
"10.1101/2022.04.25.22274285";"sciscore";"6";"5"
"10.1101/2022.04.25.22274285";"registration_statement";"FALSE";"TRUE"
"10.1101/2022.04.25.22274291";"sciscore";"4";"5"
"10.1101/2022.04.25.22274291";"funding_statement";"FALSE";"TRUE"
"10.1101/2022.04.27.22274400";"ethics_value1";"2.5 Ethics This study received ethics approval from North York General Hospital Research Ethics Board (REB ID: NYGH 20-0014).";"Using descriptive time series plots we visually compare how our NLP derived primary care COVID-19 positivity series correlates with other known COVID-19 time series externally derived from Toronto Public Health, including: 1) lab confirmed COVID-19 cases, 2) COVID-19 hospitalizations, 3) COVID-19 ICU admissions, and 4) COVID-19 intubations [Toronto Public Health, 2022]. 2.5 Ethics: This study received ethics approval from North York General Hospital Research Ethics Board (REB ID: NYGH 20-0014)."
"10.1101/2022.04.27.22274400";"coi_statement";"FALSE";"TRUE"
"10.1101/2022.04.27.22274400";"funding_statement";"FALSE";"TRUE"
"10.1101/2022.04.27.489750";"coi_statement";"FALSE";"TRUE"
"10.1101/2022.04.28.489859";"jet_pages";"1";"0"
"10.1101/2022.04.28.489859";"sciscore";"5";"4"
"10.1101/2022.04.28.489859";"has_jet_pages";"TRUE";"FALSE"
"10.1101/2022.04.29.22274455";"sciscore";"7";"6"
"10.1101/2022.04.29.22274455";"Attrition";"13 Exclusion criteria Additional exclusions include specimens collected from participants for whom: the reason for testing was the confirmation of COVID-19 recovery or confirmation of a positive RADT; vaccination date or interval between doses was invalid; first dose was received <21 days or second or third doses <7 days before testing; or a non-mRNA vaccine (Astra-Zeneca or Janssen) was received.";"notdetected."
"10.1101/2022.04.29.22274455";"Subject Demographics";"Methods Study design Test-negative design was conducted among community-dwelling residents >=12years-old in the province of Quebec, Canada with specimen collection between December 26 (epi-week 52), 2021 and March 12 (epi-week 10), 2022 tested for SARS-CoV-2 by nucleic acid amplification testing (NAAT).";"Study design: Test-negative design was conducted among community-dwelling residents ≥12-years-old in the province of Quebec, Canada with specimen collection between December 26 (epi-week 52), 2021 and March 12 (epi-week 10), 2022 tested for SARS-CoV-2 by nucleic acid amplification testing (NAAT)."
"10.1101/2022.04.29.22274455";"funding_statement";"FALSE";"TRUE"
"10.1101/2022.04.29.22274455";"attrition_detected";"TRUE";"FALSE"
"10.1101/2022.04.29.22274481";"trial_n_detected";"TRUE";"FALSE"
"10.1101/2022.04.29.22274481";"sciscore";"4";"3"
"10.1101/2022.04.29.22274486";"trial_n_detected";"TRUE";"FALSE"
"10.1101/2022.04.29.490044";"sciscore";"3";"0"
"10.1101/2022.04.29.490044";"Randomization";"notdetected.";"notrequired."
"10.1101/2022.04.29.490044";"Blinding";"notdetected.";"notrequired."
"10.1101/2022.04.29.490044";"Power Analysis";"notdetected.";"notrequired."
"10.1101/2022.05.04.22274675";"sciscore";"1";"4"
"10.1101/2022.05.04.22274675";"funding_statement";"FALSE";"TRUE"
"10.1101/2022.05.05.22274721";"sciscore";"4";"3"
"10.1101/2022.05.05.22274721";"ethics_value1";"Funding University of Bristol; UK Medical Research Council; British Heart Foundation; European Union Horizon 2020; Wellcome Trust and The Royal Society; National Institute of Health Research; UK Economic and Social Research Council Introduction Studies have sought to identify risk factors for SARS-CoV-2 infection and COVID-19 disease using a range of existing studies, new data sources such as novel surveillance sampling,1,2 and the analysis of routinely collected electronic healthcare records.";"notrequired."
"10.1101/2022.05.05.22274721";"Power Analysis";"6 Using maximal data is desirable for statistical power.";"notdetected."
"10.1101/2022.05.05.22274721";"funding_statement";"FALSE";"TRUE"
"10.1101/2022.05.05.22274721";"ethics_statement_detected";"TRUE";"FALSE"
"10.1101/2022.05.05.22274721";"power_analysis_detected";"TRUE";"FALSE"
"10.1101/2022.05.05.22274721";"ethics_titles";"Field Sample Permit,NA,NA";"NA,NA,NA"
"10.1101/2022.05.06.22274771";"trial_n_detected";"TRUE";"FALSE"
"10.1101/2022.05.06.22274782";"sciscore";"3";"2"
"10.1101/2022.05.06.22274782";"ethics_value1";"Methods Study Design This retrospective cohort study was performed at ICES, previously the Institute for Clinical Evaluative Sciences, which is an independent, non-profit research institute funded by the Ontario Ministry of Health and Long-Term Care and has legal status under Ontario's Personal Health Information Protection Act (section 45) allowing collection and analysis of health care and demographic data, without consent, for health system evaluation and improvement.";"notrequired."
"10.1101/2022.05.06.22274782";"coi_statement";"FALSE";"TRUE"
"10.1101/2022.05.06.22274782";"ethics_statement_detected";"TRUE";"FALSE"
"10.1101/2022.05.06.22274782";"ethics_titles";"Field Sample Permit,NA,NA";"NA,NA,NA"
"10.1101/2022.05.09.22274870";"coi_statement";"FALSE";"TRUE"
"10.1101/2022.05.09.22274870";"funding_statement";"FALSE";"TRUE"
"10.1101/2022.05.09.491201";"ethics_title1";"Field Sample Permit";"Consent"
"10.1101/2022.05.09.491201";"ethics_value1";"METHODS 285 Enrollment of COVID-19 vaccinees and human sample collection 286 This work results from a collaboration with the Azienda Ospedaliera Universitaria Senese, Siena (IT) that 287 provided samples from COVID-19 vaccinated donors, of both sexes, who gave their written consent.";"Enrollment of COVID-19 vaccinees and human sample collection: This work results from a collaboration with the Azienda Ospedaliera Universitaria Senese, Siena (IT) that provided samples from COVID-19 vaccinated donors, of both sexes, who gave their written consent."
"10.1101/2022.05.09.491201";"ethics_title2";"Consent";"IRB"
"10.1101/2022.05.09.491201";"ethics_value2";"METHODS 285 Enrollment of COVID-19 vaccinees and human sample collection 286 This work results from a collaboration with the Azienda Ospedaliera Universitaria Senese, Siena (IT) that 287 provided samples from COVID-19 vaccinated donors, of both sexes, who gave their written consent.";"The study was approved by the Comitato Etico di Area Vasta Sud Est (CEAVSE) ethics committees"
"10.1101/2022.05.09.491201";"Sex as a biological variable";"METHODS 285 Enrollment of COVID-19 vaccinees and human sample collection 286 This work results from a collaboration with the Azienda Ospedaliera Universitaria Senese, Siena (IT) that 287 provided samples from COVID-19 vaccinated donors, of both sexes, who gave their written consent.";"Enrollment of COVID-19 vaccinees and human sample collection: This work results from a collaboration with the Azienda Ospedaliera Universitaria Senese, Siena (IT) that provided samples from COVID-19 vaccinated donors, of both sexes, who gave their written consent."
"10.1101/2022.05.09.491201";"ethics_titles";"Field Sample Permit,Consent,IRB";"Consent,IRB,NA"
"10.1101/2022.05.10.22274866";"registration_statement";"FALSE";"TRUE"
"10.1101/2022.05.10.22274889";"coi_statement";"FALSE";"TRUE"
"10.1101/2022.05.10.22274892";"Inclusion and Exclusion Criteria";"The protocol for the BASIL pilot study was preregistered (ISRCTN94091479) on June 9, 2020. Participant Selection Sixteen study participants were interviewed from a pool of 86 study participants from the BASIL pilot study who consented to take part in an interview at initial recruitment (inclusion criteria: aged 65 years or over with two or more physical LTCs).";"Participant Selection: Sixteen study participants were interviewed from a pool of 86 study participants from the BASIL pilot study who consented to take part in an interview at initial recruitment (inclusion criteria: aged 65 years or over with two or more physical LTCs)."
"10.1101/2022.05.10.22274892";"Subject Demographics";"The protocol for the BASIL pilot study was preregistered (ISRCTN94091479) on June 9, 2020. Participant Selection Sixteen study participants were interviewed from a pool of 86 study participants from the BASIL pilot study who consented to take part in an interview at initial recruitment (inclusion criteria: aged 65 years or over with two or more physical LTCs).";"Participant Selection: Sixteen study participants were interviewed from a pool of 86 study participants from the BASIL pilot study who consented to take part in an interview at initial recruitment (inclusion criteria: aged 65 years or over with two or more physical LTCs)."
"10.1101/2022.05.10.22274892";"coi_statement";"FALSE";"TRUE"
"10.1101/2022.05.10.22274892";"funding_statement";"FALSE";"TRUE"
"10.1101/2022.05.10.491349";"sciscore";"5";"4"
"10.1101/2022.05.11.22274884";"funding_statement";"FALSE";"TRUE"
"10.1101/2022.05.11.22274949";"sciscore";"2";"0"
"10.1101/2022.05.11.22274949";"ethics_value1";"All participants were consented via written and oral consent prior to providing saliva samples.";"notrequired."
"10.1101/2022.05.11.22274949";"Inclusion and Exclusion Criteria";"Although the viral N gene was originally included in the multiplexed qPCR assays during previous testing, it is excluded in this study as both the E and RdRP targets are sufficient for detecting the presence of the viral genome in the saliva samples.";"notrequired."
"10.1101/2022.05.11.22274949";"Attrition";"notdetected.";"notrequired."
"10.1101/2022.05.11.22274949";"Sex as a biological variable";"notdetected.";"notrequired."
"10.1101/2022.05.11.22274949";"Subject Demographics";"notdetected.";"notrequired."
"10.1101/2022.05.11.22274949";"Randomization";"notdetected.";"notrequired."
"10.1101/2022.05.11.22274949";"Blinding";"notdetected.";"notrequired."
"10.1101/2022.05.11.22274949";"Power Analysis";"notdetected.";"notrequired."
"10.1101/2022.05.11.22274949";"registration_statement";"FALSE";"TRUE"
"10.1101/2022.05.11.22274949";"ethics_statement_detected";"TRUE";"FALSE"
"10.1101/2022.05.11.22274949";"inclusion_criteria_detected";"TRUE";"FALSE"
"10.1101/2022.05.11.22274949";"ethics_titles";"Consent,IRB,NA";"NA,NA,NA"
"10.1101/2022.05.11.22274949";"has_consent";"TRUE";"FALSE"
"10.1101/2022.05.11.22274949";"has_IRB_or_consent";"TRUE";"FALSE"
"10.1101/2022.05.12.22274973";"funding_statement";"FALSE";"TRUE"
"10.1101/2022.05.12.22274989";"sciscore";"2";"3"
"10.1101/2022.05.12.22274989";"ethics_value1";"notrequired.";"The trial and the Investigational New Drug application were approved by the ethics committee of the Faculty of Medicine, Chulalongkorn University, Bangkok, and Thailand’s Food and Drug Administration, respectively."
"10.1101/2022.05.12.22274989";"Inclusion and Exclusion Criteria";"Methods Seventy-two eligible volunteers, 36 aged 18-55 (adults) followed by 36 aged 56-75 (elderly) enrolled in a dose escalation study of ChulaCov19 mRNA vaccine.";"The inclusion and exclusion criteria are shown in the Supplemental Table S1."
"10.1101/2022.05.12.22274989";"Attrition";"notrequired.";"notdetected."
"10.1101/2022.05.12.22274989";"Subject Demographics";"Methods Seventy-two eligible volunteers, 36 aged 18-55 (adults) followed by 36 aged 56-75 (elderly) enrolled in a dose escalation study of ChulaCov19 mRNA vaccine.";"Trial Design: This phase 1, open-label, dose escalation study to evaluate safety and immunogenicity of ChulaCov19 vaccine enrolled healthy participants aged 18-55 (adults, n=36) followed by a cohort aged 56-75 (elderly, n=36)."
"10.1101/2022.05.12.22274989";"coi_statement";"FALSE";"TRUE"
"10.1101/2022.05.12.22274989";"ethics_statement_detected";"FALSE";"TRUE"
"10.1101/2022.05.12.22274989";"ethics_titles";"NA,NA,NA";"IRB,Consent,NA"
"10.1101/2022.05.12.22274989";"has_consent";"FALSE";"TRUE"
"10.1101/2022.05.12.22274989";"has_IRB_or_consent";"FALSE";"TRUE"
"10.1101/2022.05.13.22275054";"Subject Demographics";"METHODS 91 Study Sample The COVID-19 Community Research Partnership (CCRP) is a prospective, multi-site cohort syndromic COVID-19 surveillance study of a convenience sample of adults (18+ years) enrolled from April 2020 through June 2021 primarily through direct email outreach at ten healthcare systems from the mid-Atlantic and southeastern United States (http://www.covid19communitystudy.org/).11 Data were collected via a secure, HIPAAcompliant, online platform through March 2022.";"Study Sample: The COVID-19 Community Research Partnership (CCRP) is a prospective, multi-site cohort syndromic COVID-19 surveillance study of a convenience sample of adults (18+ years) enrolled from April 2020 through June 2021 primarily through direct email outreach at ten healthcare systems from the mid-Atlantic and southeastern United States (http://www.covid19communitystudy.org/).11 Data were collected via a secure, HIPAA-compliant, online platform through March 2022."
"10.1101/2022.05.13.22275054";"coi_statement";"FALSE";"TRUE"
"10.1101/2022.05.13.491770";"jet_pages";"4";"0"
"10.1101/2022.05.13.491770";"Randomization";"Gene segments were cloned into AbVec6W vectors (25). colonies from each transformed plate were randomly picked and the insert was checked by performing colony PCR using nested PCR primers.";"4 colonies from each transformed plate were randomly picked and the insert was checked by performing colony PCR using nested PCR primers."
"10.1101/2022.05.13.491770";"has_jet_pages";"TRUE";"FALSE"
"10.1101/2022.05.15.22275051";"ethics_titles";"IRB,Consent,Field Sample Permit";"IRB,Consent,NA"
"10.1101/2022.05.16.22275074";"Power Analysis";"Defined by asymptomatic clinical state (40% with placebo vs 60% with TCM) at 90% power, 260 patients (130 per group) are required at p<0.05.";"2.2 Sample Size Calculation: The sample size was based on detecting a 20% difference in recovery from COVID-19 related symptoms."
"10.1101/2022.05.16.492138";"sciscore";"4";"3"
"10.1101/2022.05.16.492138";"Subject Demographics";"notrequired.";"notdetected."
"10.1101/2022.05.17.22275154";"Sex as a biological variable";"Eligible women were pregnant, lactating, or nonpregnant and of reproductive age (18 to 45) and receiving a COVID-19 mRNA vaccine booster dose (August - December 2021).";"Participant recruitment and study design: Women at two tertiary care hospitals were approached for enrollment in an Institutional Review Board (IRB)–approved (protocol #2020P003538) COVID-19 pregnancy biorepository study."
"10.1101/2022.05.17.492198";"coi_statement";"FALSE";"TRUE"
"10.1101/2022.05.20.22275359";"sciscore";"2";"3"
"10.1101/2022.05.20.22275359";"ethics_value1";"notrequired.";"Ethical Statement: The Institutional Review Board (IRB) at Duke University (protocol no. 2019-0560) and Malagasy Ethics Panel (137"
"10.1101/2022.05.20.22275359";"Inclusion and Exclusion Criteria";"notrequired.";"notdetected."
"10.1101/2022.05.20.22275359";"Attrition";"notrequired.";"notdetected."
"10.1101/2022.05.20.22275359";"Randomization";"Each simulation was initiated by randomly selecting two individuals to be exposed.";"Each SEIR simulation was initiated by randomly selecting two individuals to be infected."
"10.1101/2022.05.20.22275359";"coi_statement";"FALSE";"TRUE"
"10.1101/2022.05.20.22275359";"funding_statement";"FALSE";"TRUE"
"10.1101/2022.05.20.22275359";"registration_statement";"FALSE";"TRUE"
"10.1101/2022.05.20.22275359";"ethics_statement_detected";"FALSE";"TRUE"
"10.1101/2022.05.20.22275359";"ethics_titles";"NA,NA,NA";"IRB,NA,NA"
"10.1101/2022.05.20.22275359";"has_IRB_only";"FALSE";"TRUE"
"10.1101/2022.05.20.22275380";"coi_statement";"FALSE";"TRUE"
"10.1101/2022.05.20.22275380";"funding_statement";"FALSE";"TRUE"
"10.1101/2022.05.20.22275380";"registration_statement";"FALSE";"TRUE"
"10.1101/2022.05.20.492815";"jet_pages";"5";"0"
"10.1101/2022.05.20.492815";"sciscore";"4";"6"
"10.1101/2022.05.20.492815";"ethics_value1";"Some of the work reported here was conducted at the Simons Electron Microscopy Center (SEMC) and the National Resource for Automated Molecular Microscopy (NRAMM) and National Center for CryoEM Access and Training (NCCAT) located at the NYSBC, supported by grants from the NIH National Institute of General Medical Sciences (";"notrequired."
"10.1101/2022.05.20.492815";"Sex as a biological variable";"notdetected.";"notrequired."
"10.1101/2022.05.20.492815";"Subject Demographics";"notdetected.";"notrequired."
"10.1101/2022.05.20.492815";"is_modeling_paper";"TRUE";"FALSE"
"10.1101/2022.05.20.492815";"has_jet_pages";"TRUE";"FALSE"
"10.1101/2022.05.20.492815";"ethics_statement_detected";"TRUE";"FALSE"
"10.1101/2022.05.20.492815";"ethics_titles";"Field Sample Permit,NA,NA";"NA,NA,NA"
"10.1101/2022.05.20.492819";"sciscore";"3";"4"
"10.1101/2022.05.20.492819";"Attrition";"notrequired.";"14 datasets were rejected for the high Rfree values, they were reprocessed and inspected manually."
"10.1101/2022.05.20.492819";"funding_statement";"FALSE";"TRUE"
"10.1101/2022.05.20.492819";"attrition_detected";"FALSE";"TRUE"
"10.1101/2022.05.20.492832";"ethics_value1";"notdetected.";"notrequired."
"10.1101/2022.05.20.492832";"Subject Demographics";"notdetected.";"notrequired."
"10.1101/2022.05.20.492832";"coi_statement";"FALSE";"TRUE"
"10.1101/2022.05.21.22275413";"Randomization";"56 Mendelian randomization (MR) analysis We conducted a bidirectional MR analysis to assess the causal association between each COVID-19 related trait and VTE.";"Mendelian randomization (MR) analysis: We extracted genome-wide independent significant loci for COVID-19 related tratis (severe COVID-19, COVID-19 hospitalization and SARS-CoV-2 infection) and for VTE using the genome-wide significance threshold P-value<5×10−8, clumped at LD threshold r2=0.01 and clump size 500kb."
"10.1101/2022.05.21.22275413";"is_modeling_paper";"FALSE";"TRUE"
"10.1101/2022.05.21.22275413";"funding_statement";"TRUE";"FALSE"
"10.1101/2022.05.21.22275420";"Inclusion and Exclusion Criteria";"Eligibility criteria and exposure strategies.";"Eligibility criteria and exposure strategies: We included patients with at least one SARS-CoV-2 polymerase-chain-reaction (PCR) or antigen laboratory test between March 01, 2020, and November 30, 2021, for both cohorts."
"10.1101/2022.05.21.22275420";"coi_statement";"FALSE";"TRUE"
"10.1101/2022.05.24.493347";"ethics_title1";"IACUC";"Field Sample Permit"
"10.1101/2022.05.24.493347";"ethics_value1";"2.13 In vivo Centi-C10 mAb pharmacokinetic study All animal studies were performed in accordance with National Institutes of Health guidelines and with the approval of the Stanford Administrative Panel on Laboratory Animal Care (APLAC-32109).";"At regular intervals, aliquots of the supernatant were taken for measurement in the plate reader as described above, and the sampled volume was replaced with PBS. 2.6 In vitro diffusivity measurements: All fluorescence recovery after photobleaching (FRAP) experiments were conducted in the Stanford University Cell Sciences Imaging Facility (CSIF) at room temperature or 37 °C."
"10.1101/2022.05.24.493347";"Attrition";"Data points shown as mean +- SD (n = 3 prior to 24 hrs, otherwise n = 6; for gel group, n >= 4 after day 63); calculated PK values shown as mean +- SE. 7: Bioavailability and neutralizing activity of subcutaneously delivered Centi-C10. a) Timecourse of pharmacokinetic study. b) Bioavailability quantified by the area under the curve (AUC) of the Centi-C10 pharmacokinetic profiles by ELISA through day 42 normalized by AUC of the IV bolus group (mean +- SE, n=6 mice/group); p-value determined by two-sided unpaired t-test. c) Neutralizing activity of Centi-C10 from mouse serum 7 days post-administration as determined by spike-pseudotyped lentivirus neutralization assay (mean +- SD, n=6 mice/group, assayed in duplicate).";"notdetected."
"10.1101/2022.05.24.493347";"is_modeling_paper";"TRUE";"FALSE"
"10.1101/2022.05.24.493347";"attrition_detected";"TRUE";"FALSE"
"10.1101/2022.05.24.493347";"ethics_titles";"IACUC,NA,NA";"Field Sample Permit,IACUC,NA"
"10.1101/2022.05.25.22275586";"sciscore";"5";"3"
"10.1101/2022.05.25.22275586";"registration_statement";"FALSE";"TRUE"
"10.1101/2022.05.25.22275592";"sciscore";"1";"4"
"10.1101/2022.05.25.22275592";"Sex as a biological variable";"Methods Using the linked administrative health databases from Manitoba, Canada, we conducted a quasiexperimental study among all pregnant women, comparing 3.5 years pre-pandemic (1 October 2016 to 29 February 2020) to the first year of the pandemic (1 March 2020 to 31 March 2021).";"35 Exposure and Outcomes: Pregnant women exposed to the pandemic restrictions during the first and second waves between March 1, 2020, and March 31, 2021, were compared to those who were pregnant before the pandemic period."
"10.1101/2022.05.25.22275592";"is_modeling_paper";"TRUE";"FALSE"
"10.1101/2022.05.25.22275610";"Attrition";"BA.2.3 was first detected from two cases collected on 2022- 01-11 in the Gulf Coast and the Anchorage-Mat Su regions of Alaska.";"notrequired."
"10.1101/2022.05.25.22275610";"coi_statement";"FALSE";"TRUE"
"10.1101/2022.05.25.22275610";"attrition_detected";"TRUE";"FALSE"
"10.1101/2022.05.26.22275279";"funding_statement";"FALSE";"TRUE"
"10.1101/2022.05.26.22275279";"registration_statement";"FALSE";"TRUE"
"10.1101/2022.05.26.22275631";"trial_n_detected";"TRUE";"FALSE"
"10.1101/2022.05.26.22275631";"Subject Demographics";"Similar protective effects of nirmatrelvir/ritonavir were observed across vaccination status (fully vaccinated versus otherwise) and age (dichotomized at 65 years), whereas those for molnupiravir were less consistent.";"Study design and data sources: A territory-wide observational study was conducted to examine the effectiveness of oral antiviral treatment against COVID-19 mortality or hospitalization in non-institutionalized, aged 18 or above, COVID-19 patients in Hong Kong Special Administrative Region, China, during the Omicron BA.2 wave from 1st January 2022 onward."
"10.1101/2022.05.27.22275037";"ethics_title1";"IRB";"Euthanasia Agents"
"10.1101/2022.05.27.22275037";"ethics_value1";"It was approved by the Institutional Review Board at Weill Cornell Medicine with a waiver of informed consent (no. 20-04021909).";"Time-dependent confounders included heart rate, pulse oximetry percentage, respiratory rate, temperature, blood pressure (systolic and diastolic), BUN-creatinine ratio, creatinine, neutrophils, lymphocytes, platelets, bilirubin, blood glucose, D-dimers, C-reactive protein, activated partial thromboplastin time, prothrombin time, arterial partial pressure of oxygen, and arterial partial pressure of carbon dioxide, and level of supplemental oxygen support."
"10.1101/2022.05.27.22275037";"Inclusion and Exclusion Criteria";"Population Inclusion criteria is adult COVID-19 positive patients who were admitted to NYPH's Cornell, Lower Manhattan, or Queens locations.";"2.1.1 Population: Inclusion criteria is all adult patients with COVID-19 who were admitted to New-York-Presbyterian Hospital (NYPH)/Weill Cornell, Lower Manhattan Hospital, or NYPH Queens."
"10.1101/2022.05.27.22275037";"Randomization";"Hypothetical treatment regime Patients would be randomized on their first day of hospitalization to receive either (1)standard of care therapy (without corticosteroids) or (2)standard of care plus a corticosteroid regimen to be administered if and when criteria for severe hypoxia are met.";"The estimand principle is advocated by the Food and Drug Administration for the analysis of randomized trials(23), and we argue that it should also be followed by studies that seek to establish causal relations by analyzing observational data."
"10.1101/2022.05.27.22275037";"funding_statement";"FALSE";"TRUE"
"10.1101/2022.05.27.22275037";"ethics_titles";"IRB,Consent,NA";"Euthanasia Agents,NA,NA"
"10.1101/2022.05.27.22275037";"has_consent";"TRUE";"FALSE"
"10.1101/2022.05.27.22275037";"has_IRB_or_consent";"TRUE";"FALSE"
"10.1101/2022.05.27.22275037";"is_animal_study";"FALSE";"TRUE"
"10.1101/2022.05.27.22275673";"ethics_value1";"All protocols were approved by the Hamilton Integrated Research Ethics Board and other site-specific research ethics boards, and informed consent was obtained.";"All protocols were approved by the Hamilton Integrated Research Ethics Board, and informed consent was obtained."
"10.1101/2022.05.27.22275673";"ethics_value2";"All protocols were approved by the Hamilton Integrated Research Ethics Board and other site-specific research ethics boards, and informed consent was obtained.";"All protocols were approved by the Hamilton Integrated Research Ethics Board, and informed consent was obtained."
"10.1101/2022.05.27.22275673";"Subject Demographics";"For this manuscript, humoral and cellular data were retrospectively assessed in context of CMV serostatus from a cohort of 186 participants, 65 years of age and older.";"Participant Recruitment and Blood Collection: Blood was collected from 188 participants, 65 years of age and older, in assisted living facilities (3 retirement homes and 14 nursing homes), in Ontario, Canada, between March and December 2021."
"10.1101/2022.05.27.493400";"coi_statement";"FALSE";"TRUE"
"10.1101/2022.05.28.22275432";"sciscore";"4";"3"
"10.1101/2022.05.28.22275432";"Attrition";"The rise of active cases of November with respect to October is analogous to a change of 59 cases (3,234 cases on 1 November - 3,293 on 26 November).";"notrequired."
"10.1101/2022.05.28.22275432";"is_modeling_paper";"TRUE";"FALSE"
"10.1101/2022.05.28.22275432";"attrition_detected";"TRUE";"FALSE"
"10.1101/2022.05.30.494036";"coi_statement";"FALSE";"TRUE"
"10.1101/2022.05.31.22275835";"sciscore";"2";"1"
"10.1101/2022.05.31.22275835";"Sex as a biological variable";"Omicron cases were similar in terms of age (median = 33 and 30 years respectively) and sex (49.3% vs 50.1% female, respectively), but not vaccination status: 87.2% of Omicron cases had received at least one vaccine dose, compared to only 55.4% of Delta cases.";"notrequired."
"10.1101/2022.05.31.22275835";"funding_statement";"FALSE";"TRUE"
"10.1101/2022.05.31.22275835";"sex_variable_detected";"TRUE";"FALSE"
"10.1101/2022.05.31.494162";"Inclusion and Exclusion Criteria";"Inclusion criteria required that subjects were symptomatic (fever, chills, conjunctival congestion, nasal congestion, headaches, cough, sputum production, sore throat, shortness of breath, nausea or vomiting, diarrhea, myalgia, fatigue, rash, lymphadenopathy, or confusion) and had a physician-ordered SARS-CoV- test performed in the course of their normal clinical care.";"Study participants: The patients included in this study were part of a prospective observational cohort of subjects with COVID-19-related symptoms who presented to Barnes-Jewish Hospital or affiliated Barnes-Jewish Hospital testing sites in Saint Louis, Missouri, USA, between March and September of 2020."
"10.1101/2022.05.31.494162";"coi_statement";"FALSE";"TRUE"
"10.1101/2022.05.31.494211";"coi_statement";"FALSE";"TRUE"
"10.1101/2022.06.01.22275778";"Sex as a biological variable";"Biological sex is one of the factors that potentially moderate the effect of pandemic associated changes on young people, since it is known that insomnia is more common among females than males since puberty (9).";"notdetected."
"10.1101/2022.06.01.22275778";"Randomization";"Method As part of a territory-wide epidemiological study in Hong Kong, this cross-sectional study recruited primary and secondary school students by stratified random sampling.";"The study adopted a two-stage random sampling method."
"10.1101/2022.06.01.22275778";"sex_variable_detected";"TRUE";"FALSE"
"10.1101/2022.06.01.494373";"trial_n_detected";"TRUE";"FALSE"
"10.1101/2022.06.01.494373";"Randomization";". A. Blank et al., Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial.";"notdetected."
"10.1101/2022.06.01.494373";"coi_statement";"FALSE";"TRUE"
"10.1101/2022.06.01.494373";"randomization_detected";"TRUE";"FALSE"
"10.1101/2022.06.01.494451";"coi_statement";"FALSE";"TRUE"
"10.1101/2022.06.02.494567";"trial_n_detected";"TRUE";"FALSE"
"10.1101/2022.06.03.494642";"coi_statement";"FALSE";"TRUE"
"10.1101/2022.06.05.493249";"sciscore";"3";"2"
"10.1101/2022.06.05.493249";"ethics_value1";"Funds This work was supported by National Natural Science Foundation of China (11902023), National Key R&D Program of China (2021YFC2103903) and Open Project Fund (pilab1902) of the State Key Laboratory of Precision Measuring Technology and Instruments (Tianjin University).";"notrequired."
"10.1101/2022.06.05.493249";"coi_statement";"FALSE";"TRUE"
"10.1101/2022.06.05.493249";"ethics_statement_detected";"TRUE";"FALSE"
"10.1101/2022.06.05.493249";"ethics_titles";"Field Sample Permit,NA,NA";"NA,NA,NA"
"10.1101/2022.06.05.494856";"funding_statement";"FALSE";"TRUE"
"10.1101/2022.06.06.22275865";"jet_pages";"1";"0"
"10.1101/2022.06.06.22275865";"Attrition";"Proliferation assay T cell proliferation assessed the magnitude of memory responses to SARS-CoV2 spike, M and N protein in the CD4+ and CD8+ T cell pool in 73 individuals selected for the ICS assay, with 27 participants from the BNT162b2 short interval group (16 naive and 11 with hybrid immunity), 27 participants from the BNT162b2 long interval group (15 naive and 12 with hybrid immunity) and 19 participants from the AZD1222 group (8 naive and 11 with hybrid immunity).";"Proliferation assay: T cell proliferation assessed the magnitude of memory responses to SARS-CoV2 spike, M and N protein in the CD4+ and CD8+ T cell pool in 73 individuals selected for the ICS assay, with 27 participants from the BNT162b2 short interval group (16 naïve and 11 previously infected), 27 participants from the BNT162b2 long interval group (15 naïve and 12 previously infected) and 19 participants from the AZD1222 group (8 naïve and 11 previously infected)."
"10.1101/2022.06.06.22275865";"has_jet_pages";"TRUE";"FALSE"
"10.1101/2022.06.06.22276032";"funding_statement";"FALSE";"TRUE"
"10.1101/2022.06.06.22276032";"registration_statement";"FALSE";"TRUE"
"10.1101/2022.06.06.494494";"jet_pages";"3";"0"
"10.1101/2022.06.06.494494";"trial_n_detected";"TRUE";"FALSE"
"10.1101/2022.06.06.494494";"coi_statement";"FALSE";"TRUE"
"10.1101/2022.06.06.494494";"has_jet_pages";"TRUE";"FALSE"
"10.1101/2022.06.07.22276055";"sciscore";"5";"4"
"10.1101/2022.06.07.22276055";"Attrition";"Three cases of Delta variant infections (GISAID ID: EPI_ISL_2885447, EPI_ISL_2885451, and EPI_ISL_2885452) were first confirmed by clinical tests on June 27 and reported on July 9 in Champaign County (Fig. S8).";"notrequired."
"10.1101/2022.06.07.22276055";"coi_statement";"FALSE";"TRUE"
"10.1101/2022.06.07.22276055";"funding_statement";"FALSE";"TRUE"
"10.1101/2022.06.07.22276055";"attrition_detected";"TRUE";"FALSE"
"10.1101/2022.06.07.22276117";"trial_n_detected";"TRUE";"FALSE"
"10.1101/2022.06.07.22276117";"sciscore";"3";"2"
"10.1101/2022.06.09.22276192";"ethics_value1";"The antibody index is a numerical representation of 114 the measured fluorescence signal given off by the test reaction that took place within the F2400 115 Analyzer. 116 117 Ethical Consideration: All research activities and protocols were approved by the Committee for 118 Human Research and Ethics at the University of Energy and Natural Resources with reference 119 number CHRE/AP/09/021.";"Ethical Consideration: All research activities and protocols were approved by the Committee for Human Research and Ethics at the University of Energy and Natural Resources with reference number CHRE/AP/09/021."
"10.1101/2022.06.09.22276228";"ethics_value1";"SS3501 et seq), and were determined to be public health surveillance with waiver of informed consent by institutional review boards at CDC and each enrolling site.";"C.F.R. part 46.102(l)(2), 21 C.F.R. part 56; 42 U.S.C. §241(d); 5 U.S.C. §552a; 44 U.S.C. §3501 et seq), and were determined to be public health surveillance with waiver of informed consent by institutional review boards at CDC and each enrolling site."
"10.1101/2022.06.09.22276228";"ethics_value2";"SS3501 et seq), and were determined to be public health surveillance with waiver of informed consent by institutional review boards at CDC and each enrolling site.";"C.F.R. part 46.102(l)(2), 21 C.F.R. part 56; 42 U.S.C. §241(d); 5 U.S.C. §552a; 44 U.S.C. §3501 et seq), and were determined to be public health surveillance with waiver of informed consent by institutional review boards at CDC and each enrolling site."
"10.1101/2022.06.10.22276234";"registration_statement";"FALSE";"TRUE"
"10.1101/2022.06.10.22276268";"funding_statement";"TRUE";"FALSE"
"10.1101/2022.06.11.22276272";"registration_statement";"FALSE";"TRUE"
"10.1101/2022.06.12.22276088";"sciscore";"3";"2"
"10.1101/2022.06.12.22276088";"ethics_value1";"notrequired.";"The protocol was approved by the ethics committees at all participating centers."
"10.1101/2022.06.12.22276088";"Inclusion and Exclusion Criteria";"notrequired.";"notdetected."
"10.1101/2022.06.12.22276088";"Attrition";"Patients received either opaganib (n=230; 500mg twice daily) or matching placebo (n=233) for 14 days.";"notdetected."
"10.1101/2022.06.12.22276088";"Sex as a biological variable";"notrequired.";"notdetected."
"10.1101/2022.06.12.22276088";"Subject Demographics";"notrequired.";"notdetected."
"10.1101/2022.06.12.22276088";"Randomization";"Methods A randomized, placebo-controlled, double-blind phase 2/3 trial was conducted in 60 sites worldwide from August 2020 to July 2021.";"STUDY SETTINGS AND TRIAL DESIGN: This clinical trial was a multicenter, phase 2/3, randomized, double-blind, placebo-controlled, opaganib treatment study involving patients diagnosed with COVID-19 infection defined by eligibility criteria generally aligned with the World Health Organization (WHO) Ordinal Scale for Clinical Improvement level 5."
"10.1101/2022.06.12.22276088";"Blinding";"notdetected.";"Treatment assignments were blinded to the patient, investigator, and hospital staff, as well as the sponsor."
"10.1101/2022.06.12.22276088";"blinding_detected";"FALSE";"TRUE"
"10.1101/2022.06.12.22276088";"ethics_statement_detected";"FALSE";"TRUE"
"10.1101/2022.06.12.22276088";"attrition_detected";"TRUE";"FALSE"
"10.1101/2022.06.12.22276088";"ethics_titles";"NA,NA,NA";"IRB,Consent,NA"
"10.1101/2022.06.12.22276088";"has_consent";"FALSE";"TRUE"
"10.1101/2022.06.12.22276088";"has_IRB_or_consent";"FALSE";"TRUE"
"10.1101/2022.06.12.22276299";"Inclusion and Exclusion Criteria";"Review articles were excluded.";"Study design and eligibility criteria: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) approach served as template for this review [15]."
"10.1101/2022.06.12.22276299";"registration_statement";"FALSE";"TRUE"
"10.1101/2022.06.13.22276314";"limitations";"15";"0"
"10.1101/2022.06.13.22276314";"sciscore";"2";"1"
"10.1101/2022.06.13.22276314";"Inclusion and Exclusion Criteria";"The Ad26.COV2.S vaccine was excluded from this analysis due to few reports.";"notdetected."
"10.1101/2022.06.13.22276314";"limitations_detected";"TRUE";"FALSE"
"10.1101/2022.06.13.22276314";"inclusion_criteria_detected";"TRUE";"FALSE"
"10.1101/2022.06.14.496062";"jet_pages";"4";"0"
"10.1101/2022.06.14.496062";"Attrition";"Two participants were excluded after their in-house RT-qPCR results remained negative and contradicted their initial diagnosis.";"In total 126 participants were enrolled."
"10.1101/2022.06.14.496062";"coi_statement";"FALSE";"TRUE"
"10.1101/2022.06.14.496062";"has_jet_pages";"TRUE";"FALSE"
"10.1101/2022.06.15.496220";"coi_statement";"FALSE";"TRUE"
"10.1101/2022.06.16.22276392";"funding_statement";"FALSE";"TRUE"
"10.1101/2022.06.17.22276576";"sciscore";"2";"1"
"10.1101/2022.06.17.22276576";"ethics_value1";"notdetected.";"notrequired."
"10.1101/2022.06.17.22276576";"Subject Demographics";"We define the first Ui , Personal Factor as: Pi = wA NA,i NI,i + wI N0,i N0,i {0 <= wA , wI <= 1 wA + wI = 1 (Eq. 3) where wA is a weight factor for inhabitants of age, (A, i) >= 65 years old, NA,i is the total number of people A, i >= 65, wI is a weight factor for an annual income, I, i <= $50,000, NI,i is the total number of people with I, i <= $50,000, and N0,i is the total number of people living in the region i.";"We define the first Ui, Personal Factor as:where wA is a weight factor for inhabitants of age, (A, i)≥ 65 years old, NA,iis the total number of people A, i ≥ 65, wI is a weight factor for an annual income, I, i ≤ $50,000, NI,i is the total number of people with I, i ≤ $50,000, and N0,i is the total number of people living in the region i."
"10.1101/2022.06.17.22276576";"coi_statement";"FALSE";"TRUE"
"10.1101/2022.06.17.22276576";"funding_statement";"FALSE";"TRUE"
"10.1101/2022.06.21.22276720";"sciscore";"3";"2"
"10.1101/2022.06.21.22276720";"ethics_value1";"Additionally, ethical approval to conduct this research has been obtained from the Ottawa Health Sciences Research Ethics Board (OHSN REB) prior to the start of all research activities.";"notrequired."
"10.1101/2022.06.21.22276720";"Sex as a biological variable";"notdetected.";"notrequired."
"10.1101/2022.06.21.22276720";"Subject Demographics";"notdetected.";"notrequired."
"10.1101/2022.06.21.22276720";"is_modeling_paper";"FALSE";"TRUE"
"10.1101/2022.06.21.22276720";"registration_statement";"FALSE";"TRUE"
"10.1101/2022.06.21.22276720";"ethics_statement_detected";"TRUE";"FALSE"
"10.1101/2022.06.21.22276720";"ethics_titles";"IRB,NA,NA";"NA,NA,NA"
"10.1101/2022.06.21.22276720";"has_IRB_only";"TRUE";"FALSE"
"10.1101/2022.06.24.22276144";"sciscore";"1";"4"
"10.1101/2022.06.24.22276144";"ethics_value1";"notrequired.";"Study approval: This study was registered with Clinical Trials Ontario and was approved by both the Sunnybrook Health Sciences Centre Research Ethics Board and locally by the St."
"10.1101/2022.06.24.22276144";"Inclusion and Exclusion Criteria";"notrequired.";"All adult patients (aged ≥ 18 years) who had received a kidney transplant and had a functioning allograft were considered eligible for inclusion."
"10.1101/2022.06.24.22276144";"Attrition";"notrequired.";"notdetected."
"10.1101/2022.06.24.22276144";"Sex as a biological variable";"notrequired.";"notdetected."
"10.1101/2022.06.24.22276144";"Subject Demographics";"notrequired.";"All adult patients (aged ≥ 18 years) who had received a kidney transplant and had a functioning allograft were considered eligible for inclusion."
"10.1101/2022.06.24.22276144";"coi_statement";"FALSE";"TRUE"
"10.1101/2022.06.24.22276144";"ethics_statement_detected";"FALSE";"TRUE"
"10.1101/2022.06.24.22276144";"inclusion_criteria_detected";"FALSE";"TRUE"
"10.1101/2022.06.24.22276144";"subject_demographics_detected";"FALSE";"TRUE"
"10.1101/2022.06.24.22276144";"ethics_titles";"NA,NA,NA";"IRB,Consent,NA"
"10.1101/2022.06.24.22276144";"has_consent";"FALSE";"TRUE"
"10.1101/2022.06.24.22276144";"has_IRB_or_consent";"FALSE";"TRUE"
"10.1101/2022.06.28.22276983";"Subject Demographics";"Methods: We conducted a cohort study using de-identified data from the Western Cape Provincial Health Data Centre (WCPHDC) of public sector patients aged >=20 years with a laboratory confirmed COVID-19 diagnosis (positive SARS-CoV-2 PCR or antigen test).";"We conducted a cohort study using de-identified data from the Western Cape Provincial Health Data Centre (WCPHDC) of public sector patients aged ≥20 years with a laboratory confirmed COVID-19 diagnosis (positive SARS-CoV-2 PCR or antigen test)."
"10.1101/2022.06.28.22276983";"funding_statement";"FALSE";"TRUE"
"10.1101/2022.06.29.22277065";"sciscore";"3";"2"
"10.1101/2022.06.29.22277065";"Inclusion and Exclusion Criteria";"The exclusion of immigrant populations from the safety net(48), anemic workplace protections(49), and crowded housing(50) contributed to the large impact of COVID-19 among U.S.";"Data from Canada exclude deaths in the Yukon (<0.1% of Canada’s population)."
"10.1101/2022.06.29.22277065";"Attrition";"Ninety-one percent of the increase in under-65 mortality in the U.S. from 2019 to 2021 would have been averted if the U.S. had the age-specific mortality rates of its peers.";"notrequired."
"10.1101/2022.06.29.22277065";"Power Analysis";"Beginning with the genocide of native populations and the enslavement of people of African descent,(35, 36) and continuing through a long history of discrimination, segregation, and exclusion, U.S. policies have directly harmed the health of Black and Native Americans (21), and these harms have reverberated through the intergenerational transfer of resources, power, and health.";"notdetected."
"10.1101/2022.06.29.22277065";"funding_statement";"FALSE";"TRUE"
"10.1101/2022.06.29.22277065";"power_analysis_detected";"TRUE";"FALSE"
"10.1101/2022.06.29.22277065";"attrition_detected";"TRUE";"FALSE"
"10.1101/2022.06.29.498191";"sciscore";"4";"5"
"10.1101/2022.06.29.498191";"funding_statement";"FALSE";"TRUE"
